Dual targeting of EphA2 and FAK in ovarian carcinoma. - Wikidata - awgldk - TriplyDB

Dual targeting of EphA2 and FAK in ovarian carcinoma.

Dual targeting of EphA2 and FAK in ovarian carcinoma.

http://www.wikidata.org/entity/Q37357254

about

Delivery of gene silencing agents for breast cancer therapy Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance.Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis.Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma.Eph receptors and ephrins in cancer: bidirectional signalling and beyond.Prognostic biomarkers in ovarian cancer.Emerging strategies for EphA2 receptor targeting for cancer therapeutics.Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles.Functional roles of Src and Fgr in ovarian carcinoma.Src family kinases and paclitaxel sensitivity.Eph receptors and ephrins as targets for cancer therapy.Therapeutic advances in women's cancers Therapeutic silencing of KRAS using systemically delivered siRNAs.Paraneoplastic thrombocytosis in ovarian cancer.Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid.Toward personalized cancer nanomedicine - past, present, and future.Indium-Labeling of siRNA for Small Animal SPECT Imaging.Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma.RNA interference in the clinic: challenges and future directions.Strategies for tumor-directed delivery of siRNA.Leveraging therapeutic potential of multi-targeted siRNA inhibitors.Challenging the future of siRNA therapeutics against cancer: the crucial role of nanotechnology.Eph receptors and ephrins: therapeutic opportunities.Recent advances in siRNA delivery.Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy.Administration of PLGA nanoparticles carrying shRNA against focal adhesion kinase and CD44 results in enhanced antitumor effects against ovarian cancer.Selection of optimal combinations of target genes for therapeutic multi-gene silencing based on miRNA co-regulation.Ephrin receptor (Eph) -A1, -A2, -A4 and -A7 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.

P2860

Q27008706-0715C6FC-DEB7-4646-A32D-63D7374CA4BE Q30365844-7F334712-A673-4B7E-9660-C55BE53CB591 Q33851325-EEC03FC1-7782-44AE-AAF8-2906BACD62B4 Q33859472-D063F44D-1F8B-48F5-A5AC-59A387E1AB6D Q33904883-27FCE0DC-DA2C-461F-9B8C-0603308CAF42 Q34021365-8A03EF89-A9DD-4BE7-BB0E-CFA6245E7CFE Q34086636-7FBA5172-4E4C-4F13-960A-39902ACF8A8B Q34469271-27637D5E-2736-4952-A21D-1EFAF061CE8E Q34524860-05F973A9-3670-40A8-B003-4B1D5896C391 Q34763617-99DF7D09-67DB-4508-9048-9294D0FC1890 Q34796603-A565B8B9-6D67-4F57-BFE3-7511F48B8A8B Q35214722-7A4DF57B-69F6-413F-8994-07314F314399 Q35370195-890E57E9-AC55-4487-8BF6-C804CA52A5A4 Q35418973-C17A5F53-E5C1-45C5-9B9C-308CCA2D6D5F Q35559932-890EA03D-1E07-41BB-BA2B-4767DDA10688 Q35812402-DBE93755-40DC-4C95-8A60-6B150044CA91 Q36400401-5DB91340-7887-4DCA-B26D-9B842FDF83A5 Q36446536-8FF8D1E1-1F07-43E9-B662-538E4787DAFB Q36472802-8C2E515B-FE5B-4EDA-BC33-16D11CBFC543 Q37076674-BE24B7CA-11D7-4605-929D-46638AF9C4BB Q37086837-128D3400-4712-43B5-9556-096CA775A837 Q37373640-48637DED-7768-4AE6-B24B-9B243D6206C1 Q37625369-67D948D7-7CDD-425A-A8CF-1D748D39EDD1 Q37821230-5C21BF7A-8DE3-491D-A6EC-1F087E538A99 Q37840092-0939DDC0-7C2E-4233-AE34-2E78067D73D1 Q37855818-192CC7BF-B1BE-4682-AA3F-1E3F85D0176B Q38162098-C8C0AE29-F141-4D9F-AAC3-32BCF8DFF3F4 Q38257853-E371243A-07C8-4AF3-9F9E-3007B32F560F Q38648525-F33B128D-4320-4FC7-B9BE-F6946371F255 Q42032794-824CF8F5-6A44-420B-9A9A-796F380B55CD Q44733095-21B222CF-5DB5-4765-87D7-3393C1288508 Q45887067-15354EDA-6495-4D22-9298-4C803F8B1DC6 Q51205063-75E756D8-BD6F-4AF8-9AE9-0ABD0BD0D24A

P2860

Dual targeting of EphA2 and FAK in ovarian carcinoma.

http://www.wikidata.org/entity/Q37357254

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Dual targeting of EphA2 and FAK in ovarian carcinoma.

@en

Dual targeting of EphA2 and FAK in ovarian carcinoma.

@nl

type

label

Dual targeting of EphA2 and FAK in ovarian carcinoma.

@en

Dual targeting of EphA2 and FAK in ovarian carcinoma.

@nl

prefLabel

Dual targeting of EphA2 and FAK in ovarian carcinoma.

@en

Dual targeting of EphA2 and FAK in ovarian carcinoma.

@nl

P1433

Q37357254-5EF37A06-D4CA-4D66-ADD9-7FE52F442BD1

P1476

Q37357254-BF9DAC8E-C8E0-47C7-8298-75C571B06DEC

P2093

Q37357254-0D38766D-ACC6-44DA-A07E-B5F01099D381

Q37357254-12CECB79-47C6-48D9-B538-A0523F8DACFD

Q37357254-17ED0303-C11E-4E19-BC84-E28BAC005FF5

Q37357254-419360D1-B710-40D1-ADC2-9C56615BCB89

Q37357254-4911925B-249A-444E-BB43-50086395DADF

Q37357254-4C66E8D0-3071-46A8-B8EB-4301815712ED

Q37357254-62EC1F03-30B8-4F03-986D-CE69119B81CF

Q37357254-66264A57-2799-4229-AA6B-4F2A5872A801

Q37357254-6B43B9DF-37A3-472A-B34F-BAAD8B695D50

Q37357254-6ED1B7BE-9774-41BF-BEDA-EA60878BCF03

P2860

Q37357254-05CB0AF0-364B-4700-AA34-FCC10D9B8960

Q37357254-06284A29-2066-4AA8-BAA2-81E082FA9631

Q37357254-1536EEB8-6AE5-4692-A827-567F5E8BA9DC

Q37357254-158DA772-7475-45ED-A97F-7588D4853005

Q37357254-1DD6E070-C3FF-4140-A77A-0911EC90DA44

Q37357254-28E64F67-4062-439F-8D16-ADCE94668FDD

Q37357254-2F574167-EA27-43F8-87C9-7E7033134A72

Q37357254-30D58965-C6F0-4C6C-9207-5CB95F2D18A2

Q37357254-31B5B38F-7260-4B35-A00C-4EBF764D9556

Q37357254-42FE8D3E-E068-44D4-B9A2-36D97B02A39A

P304

Q37357254-44BD2870-0ABF-47C8-8313-ABA3EF690949

P31

Q37357254-727BE3AF-2436-4CBE-A483-35C5E1AF99D4

P356

Q37357254-9B35633C-2044-4790-9F1B-59F0F0AE3492

P433

Q37357254-1E5C9B66-6ADD-4C86-8534-7656D7817BF1

P478

Q37357254-3DE4D3B8-6499-47AE-A7BE-A5B2D2AC3586

P577

Q37357254-4A9D2BC2-9695-4470-9901-8ADC0EB04C79

P5875

Q37357254-6030F2D1-813C-47FF-85BA-F9980C561E71

P698

Q37357254-0088505C-BC1B-4711-A29F-C48D26B6468F

P932

Q37357254-0EFF6112-25CF-453D-848E-4AE4D75CD109

P356

P1433

Cancer Biology and Therapy

P1476

Dual targeting of EphA2 and FAK in ovarian carcinoma.

@en

P2093

Alpa M Nick

http://www.w3.org/2001/XMLSchema#string

Anil K Sood

http://www.w3.org/2001/XMLSchema#string

Charles N Landen

http://www.w3.org/2001/XMLSchema#string

Christopher G Danes

http://www.w3.org/2001/XMLSchema#string

Chunhua Lu

http://www.w3.org/2001/XMLSchema#string

Gabriel Lopez-Berestein

http://www.w3.org/2001/XMLSchema#string

Hye-Sun Kim

http://www.w3.org/2001/XMLSchema#string

Jeong-Won Lee

http://www.w3.org/2001/XMLSchema#string

Jyotsnabaran Halder

http://www.w3.org/2001/XMLSchema#string

Keith A Baggerly

http://www.w3.org/2001/XMLSchema#string

P2860

pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions.

cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases

Differential regulation of cell motility and invasion by FAK

Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.

FAK integrates growth-factor and integrin signals to promote cell migration

'Eph'ective signaling: forward, reverse and crosstalk

Biochemical signals and biological responses elicited by the focal adhesion kinase

CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase

Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph Nomenclature Committee

Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis

P304

1027-1034

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CBT.8.11.8523

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24361554

http://www.w3.org/2001/XMLSchema#string

P698

19395869

http://www.w3.org/2001/XMLSchema#string

P932

2748749

http://www.w3.org/2001/XMLSchema#string